Coexistence of Plasma Cell Dyscrasia with Prefibrotic Stage of Primary Myelofibrosis: A Case Report by Tsirakis, George et al.
International Scholarly Research Network
ISRN Hematology
Volume 2011, Article ID 404057, 3 pages
doi:10.5402/2011/404057
Case Report
CoexistenceofPlasma Cell Dyscrasia withPreﬁbrotic Stageof
Primary Myeloﬁbrosis: ACaseReport
George Tsirakis,1 PeggyKanellou,1 MariaKaparou,1 AndrewPassam,2
Amalia Zampoulaki,1 KostasStylianou,2 and Michael G. Alexandrakis1
1Department of Haematology, University Hospital of Heraklion, 71110 Heraklion Crete, Greece
2Department of Nephrology, University Hospital of Heraklion, 71110 Heraklion Crete, Greece
Correspondence should be addressed to Michael G. Alexandrakis, alexandm@med.uoc.gr
Received 18 February 2011; Accepted 24 March 2011
Academic Editors: F. W. Quelle and J.-L. Villeval
Copyright © 2011 George Tsirakis et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Introduction. Coexistence of myeloproliferative neoplasms with lymphoproliferative syndromes has been described in the past,
whereas plasmacell dyscrasias seem to be the mostcommoncases. Case Presentation. Wepresent a case ofa 59-year-old Caucasian
female of Greek origin who presented with thrombocytosis. Clinical and laboratory investigation disclosed the presence of a
smoldering myeloma with coexisting histological and molecular characteristics of primary myeloﬁbrosis. The patient had the
acquired point mutation V617F in the JAK2 gene but not the bcr-abl rearrangement and was treated for myeloﬁbrosis with
subsequent improvement of all haematological parameters without evidence of myelomatic evolution. Conclusion.W ep r e s e n tt h e
ﬁrstcaseintheliteratureofasmolderingmyelomacoexistingwithprimarymyeloﬁbrosis.Theunderlyingpathogeneticmechanism
couldbe eitherrelated to the presence ofa pluripotent neoplasticstemcell capable to diﬀerentiate intoboth lymphoidandmyeloid
cells or be related to two separate nosologicentities.
1.Introduction
An association between plasma cell dyscrasias and myelo-
proliferative neoplasms has been previously described [1–
5]. Coexistence of multiple myeloma (MM) and primary
myeloﬁbrosis (PMF) is considered extremely rare, whereas
the association between the two clinical entities is also
unclear [4, 5]. MM and CIMF are clonal proliferations of
cells arising from diﬀerent haemopoietic elements, and the
distinction between them is based on clinical, morphologi-
cal, and laboratory features [6].
In this paper, we describe a patient with clinical and
pathological ﬁndings suggestive of coexisting myeloma and
preﬁbrotic PMF.
2.CasePresentation
A 59-year-old Caucasian female presented with generalized
malaise and headacheof7-dayduration.Noothersymptoms
were referred, and the patient was afebrile. The patient had a
prior medical history of hypertension for which she was not
receiving any speciﬁc treatment as well as hypothyroidism
for which she was receiving levothyroxine. Physical exami-
nation was unremarkable with no organomegaly or enlarged
lymph nodes. White blood cells were 10.000/μL (neutrophils
7.400/μL, lymphocytes 1.900/μL, monocytes 300/μL, and
eosinophils 400/μL) with normal morphology, haemoglobin
was 14.0g/dL, and platelet count was 1.042.000/μL, many of
which were large. Erythrocyte sedimentation rate (ESR) was
19mm/1st hour, and clottingtests were normal. Biochemical
analyses showed a raised lactate dehydrogenase (LDH =
285IU/l) and potassium (K = 5.4mEq/l). Urine analysis
was unremarkable. IgG was elevated at 3300mg/dL (normal
range 701–1545mg/dL), IgA was low at 24.5mg/dL (normal
range 48–368mg/dL), IgM was also low at 19.3mg/dL (nor-
mal range 25–170mg/dL), whereas serum β2 microglobulin
and C-reactive protein (CRP) were normal. There was
no Bence-Jones proteinurea. Serum protein electrophoresis2 ISRN Hematology
revealed a spike in the area of gamma globulins, and
serum immunoﬁxation showed monoclonal IgGκ molecule.
Karyotype was normal.
There were no lytic lesions on a skeletal survey with
X-rays and computed tomography (CT), whereas a skull
CT showed sinusitis without any ﬁndings from the central
nervous system. Gastroscopy and coloscopy did not reveal
any pathology. The spleen and the liver were normal by
ultrasound. Bone marrow examination revealed 15% cIgGκ
monoclonal plasma cell inﬁltration [CD138(+), CD56(−)]
and signiﬁcant increase in the megakaryocytes population
with variable appearance(markedly atypicalmegakaryocytes
with dense clustering of naked megakaryocytic nuclei) and
mild local ﬁbrosis with little reticulin. This image could be
explained in terms of a myeloproliferative neoplasm such as
preﬁbrotic stage of myeloﬁbrosis with concomitant existence
of a plasma cell dyscrasia. Furthermore, the patient had the
acquired point mutation V617F in the JAK2 gene, measured
bythequalitativetechniqueofARMSPCRinthewhite blood
cells of peripheral blood, but not the bcr-abl rearrangement.
Since the bone marrow inﬁltration was only 15% with the
absence of myeloma-related manifestations, the diagnosis
of myeloﬁbrosis with a smoldering IgGκ myeloma was
made. The patient was treated with hydroxyurea 1g/day
over the ﬁrst 2 months and 500mg/day thereafter. She was
also commenced on 100mg salicylic acid daily. With this
treatment, thepatient’splateletshavebeenmaintained below
400.000/μL and the bone marrow plasma cell inﬁltration at
3%, for almost ﬁve years. There is also sustained depression
of the monoclonal protein concentration at levels below
2000mg/dL.
3.Discussion
In the past, preﬁbrotic myeloﬁbrosis could be misdiagnosed
as essential thrombocythaemia (ET), and a distinction
between the two entities had been greatly emphasised by
histopathologists [7–9]. However, the natural history of
preﬁbrotic myeloﬁbrosis remains unclear, since prospective
studies are lacking, and preliminary data suggest that the
rate of progression to advanced disease may depend on
the degree of megakaryocytic dysplasia [8, 9]. According
to the latest classiﬁcation of myeloproliferative neoplasms,
the preﬁbrotic myeloﬁbrosis without splenomegaly, no true
increase of neutrophil granulopoiesis or anemia may go in
favor of ET instead of PMF.
The patient presented with clinical symptoms and lab-
oratory ﬁndings indicating the diagnosis of preﬁbrotic PMF.
Thediagnosis was documentedbythetrephinebonemarrow
biopsy which conﬁrmed mild ﬁbrosis along with abnormal
plasma cell inﬁltration and absence of the Ph chromosome
or the bcr-abl rearrangement [10]. Furthermore, the patient
had the acquired point mutation V617F in the JAK2 gene, as
has been reported by other studies [11–14].
Previous reports have cited an association between
myelomatous bone marrow inﬁltration and bone marrow
ﬁbrosis and postulate that lymphokines secreted by the
malignant cells may trigger the appearance of tumor-
associated myeloﬁbrosis [3–5, 15]. This concept is sustained
bytheknownassociationbetweenbonemarrowﬁbrosiswith
other B-cellmalignancies, suchas Walderstr¨ om’s macroglob-
ulinaemia and hairy cell leukaemia [1]. In contrast, other
studies have suggested the coexistence of two distinct clonal
diseases or the parallel, biclonal evolution of two clinical
entities originating from a common stem cell [10]. There-
fore, there is a distinction between patients with plasma cell
dyscrasia associatedwithsimplemarrowﬁbrosisandpatients
with coexistent agnogenic myeloid metaplasia [3].
The patient described here has plasma cell dyscrasia doc-
umented by the existence of IgG kappa-producing plasma
cells inﬁltrating the bone marrow and IgG paraprotein
in the serum. Furthermore, the bone marrow presented
hyperplasia of megakaryocyte lineage with marked atypia.
This feature can be observed in MM patients as a reactive
phenomenon induced by MM cells expressing factors that
regulate ﬁbroblast proliferation [16, 17]. However, the
JAK2 V617F mutation excludes the probability of reactive
thrombocytosis. Data suggest that the JAK2 V617F mutation
does not occur in nonhematological cancers and that this
mutation is uncommon in myeloid malignancies other than
the classic bcr-abl-negative myeloproliferative neoplasms
[18].
The pathogenesis underlying the coexistence of PMF and
MM could be related to either the presence of a plurip-
otent neoplastic stem cell capable to diﬀerentiate into both
lymphoid and myeloid cells or be caused by two separate
neoplastic clones. The absence of myelomatic evolutionafter
treatment for PMF may support the ﬁrst hypothesis. More-
over, essential thrombocythaemia has also been reported to
involve pluripotent stem cells capable to diﬀerentiate into
immunoglobulin producing B-lymphoid cells and myeloid
cells [19, 20].
W ec o n c l u d et h a tt oo u rk n o w l e d g e ,t h i si st h eﬁ r s tc a s e
of a patient with preﬁbrotic PMF coexisting with a MM.
Further studiesare needed in orderto clarify the pathophysi-
ologic basis of this coexistence.
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